12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

SBC-103 regulatory update

Synageva said FDA granted Orphan Drug designation for its SBC-103 to treat mucopolysaccharidosis IIIB...

Read the full 48 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >